Pancreatic Cancer Research

Clinical trialPhase 2Completed

FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial

BrUOG 318: FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial

Outcome
Results posted; single-arm, no comparison
Phase
Phase 2
Status
Completed
Study type
Interventional
Start
12 July 2016
Ended
16 March 2022
Enrollment
28 participants
Sites
1
Primary outcomes
Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer.
Sponsor type
Academic / other
Results posted
13 August 2021
Last update
6 May 2023

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Results

Primary endpoint
Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 6 May 2023
Primary outcome
Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer.Complete Response: FOLFOXA: 0 of 28Partial Response: FOLFOXA: 12 of 28Stable Disease: FOLFOXA: 12 of 28Progressive Disease: FOLFOXA: 4 of 28Values: ParticipantsTime frame: From date of start of treatment, until the date of first documented progression, whichever came first, assessed up to 3 yearsNo analysis posted for this outcome (outcome 1)
Participants
FOLFOXA: 28 started, 28 completed
Serious adverse events
FOLFOXA: 8 of 28Participants with at least one serious adverse event, of those at risk, as posted
1 secondary outcome
OS · Overall Survival for Patients With Locally Advanced Pancreatic Cancer Treated With F…
FOLFOXA 12.3 (2 to 36), n=28 [mean months, Full Range]

Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

Preliminary data suggests that FOLFOX-A may have equal or superior activity as compared to FOLFIRINOX for patients with metastatic pancreatic cancer and appears to be better tolerated with the ability to administer at least 10 cycles of therapy. Investigators therefore will evaluate FOLFOX-A in a phase II study for patient with locally advanced pancreatic cancer.

Detailed description public domain (ClinicalTrials.gov)

See summary above

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer. [From date of start of treatment, until the date of first documented progression, whichever came first, assessed up to 3 years]. Count Of Participants, Participants. Complete Response: FOLFOXA (n=28): 0. Partial Response: FOLFOXA (n=28): 12. Stable Disease: FOLFOXA (n=28): 12. Progressive Disease: FOLFOXA (n=28): 4.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Overall Survival for Patients With Locally Advanced Pancreatic Cancer Treated With FOLFOX-A [During treatment (approximately every 2 weeks for up to 6 months), then approximately every 4 months for for a maximum of 5 years]. Mean, months (Full Range). FOLFOXA (n=28): 12.3 (2 to 36).